

Crohn's Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/CA6642EC20BBEN.html>

Date: April 2022

Pages: 632

Price: US\$ 2,500.00 (Single User License)

ID: CA6642EC20BBEN

Abstracts

Crohn's Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease - Drugs In Development, 2022, provides an overview of the Crohn's Disease (Gastrointestinal) pipeline landscape.

Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Crohn's Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development

history and latest news and press releases.

The Crohn's Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 13, 42, 37, 3, 77 and 37 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 1, 1, 4 and 1 molecules, respectively.

Crohn's Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Crohn's Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Crohn's Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Crohn's Disease (Regional Enteritis) - Overview

Crohn's Disease (Regional Enteritis) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Crohn's Disease (Regional Enteritis) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development

Crohn's Disease (Regional Enteritis) - Drug Profiles

Crohn's Disease (Regional Enteritis) - Dormant Projects

Crohn's Disease (Regional Enteritis) - Discontinued Products

Crohn's Disease (Regional Enteritis) - Product Development Milestones

Featured News & Press Releases

Apr 19, 2022: People with moderate to severe uncontrolled Crohn's disease granted early access to new investigational treatment in the UK

Apr 04, 2022: Thetis Pharmaceuticals secures \$4.2 million from the Helmsley Charitable Trust to advance its first-in-class Resolvin oral therapy for Crohn's Disease

Mar 30, 2022: Redx nominates GI-targeted ROCK inhibitor, RXC008, as clinical development candidate

Mar 28, 2022: Tiziana commences Phase Ib trial of Crohn's disease antibody

Mar 24, 2022: Celltrion Healthcare wins tender to supply Remsimato the Brazilian Federal Government

Feb 28, 2022: AbbVie provides update regarding SKYRIZI (risankizumab-rzaa) for the treatment of moderate to severe Crohn's disease in the U.S.

Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn's disease

Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn's disease

Feb 20, 2022: Rapid improvement and remission in patients with refractory ulcerative

colitis and crohn's colitis after direct injection of Remestemcel-L by colonoscopy
Feb 18, 2022: The majority of adults with moderately to severely active Crohn's disease in a phase 2 study achieved clinical remission and corticosteroid-free remission through 48 weeks with TREMFYA (guselkumab)

Feb 15, 2022: Statera Biopharma announces Central Institutional Review Board approval of phase 3 clinical trial for pediatric Crohn's disease

Feb 04, 2022: Tiziana announces submission of amendment to Investigational New Drug Application to advance oral foralumab, a fully human anti-CD3 monoclonal antibody, in patients with crohn's disease

Feb 04, 2022: Mitsubishi Tanabe's 9 month sales rise fueled by strong growth in Stelara

Jan 06, 2022: Avalo reports positive phase 1b results for AVTX-002 in moderate to severe Crohn's disease patients and Presents Additional Program Updates at 2022 Investor Event

Dec 29, 2021: Statera Biopharma submits phase 3 clinical trial protocol to FDA for investigational treatment of pediatric Crohn's Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Crohn's Disease (Regional Enteritis), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Crohn's Disease (Regional Enteritis) - Dormant Projects, 2022

Crohn's Disease (Regional Enteritis) - Discontinued Products, 2022

Crohn's Disease (Regional Enteritis) - Discontinued Products, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Crohn's Disease (Regional Enteritis), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Crohn's Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CA6642EC20BBEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA6642EC20BBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

